# Transthyretin Amyloidosis Market

> Transthyretin (TTR) Amyloidosis Market Research Report Information Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), and End-User (Ambulatory Surgical Center, Clinics) and Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.64%
- **2024:** $ 5.98 Billion
- **2025:** $ 6.45 Billion
- **2035:** $ 12.18 Billion
- **Key Players:** Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Prothena Corporation (US), Akcea Therapeutics (US)

**Report ID:** MRFR/Pharma/4697-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155

---

## Market Summary

## **Transthyretin Amyloidosis Market Overview**

Transthyretin Amyloidosis (ATTR) Market Size was valued at USD 5.36 Billion in 2023. The Global Transthyretin Amyloidosis (ATTR) industry is projected to grow from USD 5.85 Billion in 2024 to USD 10.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.98% during the forecast period (2024 - 2032). 

**Latest Industry Developments in Transthyretin Amyloidosis (TTR) Market** **May 2024**

Pfizer has received FDA approval for Vyndaqel (tafamidis) as a treatment for wild-type ATTR amyloidosis, based on clinical data showing significant benefits in reducing cardiac complications.

**July 2024**

Ionis has introduced IONIS-TTR-LRx, a new antisense oligonucleotide drug, with promising clinical trials indicating stronger efficacy and improved safety compared to existing therapies.

Transthyretin Amyloidosis is a progressive disease that includes an abnormal buildup of abnormal proteins under the skin or in organs like kidneys, heart, eyes, brain, or tissues. The diseases have implications for organs and the peripheral nervous system. There are two presentations of the condition which are Transthyretin amyloid polyneuropathy and Transthyretin amyloid cardiomyopathy. 

In Transthyretin amyloid polyneuropathy, the amyloid fibrils are deposited in the peripheral nervous system and Transthyretin Amyloid cardiomyopathy, the deposits are made on the heart which could lead to heart failure. The type of the condition is majorly dependent on the type of protein that is deposited in the organs. 

The symptoms could get worse over time and varies according to the protein deposits. Amyloid buildup in the nerves can permanently affect the nervous system and eventually loss of sensation in limbs, hands, and feet. Although they primarily affect the voluntary functions of the patients, they tend to affect the involuntary body functions such as blood pressure, heart rate, digestion, and so on. The survival chances are only 7 years from the disease onset. These factors are primarily responsible for the overall growth of the Transthyretin Amyloidosis Market.

**COVID 19 Analysis:**

The pandemic has significantly affected major health concerns and various other health sectors. The physicians have tries different methods in assisting patients to offer a potential treatment. Especially physicians have found it very challenging in handling COVID-infected ATTR patients. Since Transthyretin Amyloidosis is a progressive disease, they tend to develop multi-organ complications due to COVID infection.

The delays in the diagnosis and interrupted treatment due to movement restrictions across several countries have inflicted significant risks for the patients with Transthyretin Amyloidosis. Additionally, patients and doctors found the changing trend of the treatment procedure, while ensuring to reduce the interruptions in treatments.

**Market Dynamics:**

**Drivers:**

Surgical [gene therapy](../../../reports/gene-therapy-market-8399) is considered the effective therapy for treating patients with the mutation at the early phases of the disease. Additionally, the advent of pipeline therapy in the Transthyretin Amyloidosis Market has stimulated the overall growth of the market. Moreover, the entrants of a new class of drugs and a combination of potential strategies to treat the patients are stimulating the market growth.

The increasing number of Transthyretin drug launches and increasing population that are highly susceptible to the condition are considered as the primary factors that augment the overall Transthyretin Amyloidosis Market growth. 

**Opportunities:**

Cardiac Amyloidosis is considered a rare condition for a long period, however, the recent diagnosis in several countries has shown an increasing number of Cardiac Amyloidosis who were diagnosed as heart failure. The recent therapeutic inventions have helped the survival of Transthyretin Amyloidosis patients. The increasing incidences and advent of new therapies present lucrative opportunities for the Transthyretin Amyloidosis Market growth. 

Since the condition was considered a rare occurrence, the awareness about the medication, treatment, and therapies was not much widely known in several countries. However, in recent times, the awareness regarding the condition is increasing. The drugs for the condition such as Prothena PRX004 and Proclara’s NPT189 are at the development stages and are expected to support the growth of the industry.

**Restraints:**

The awareness about the condition is increasing in the developed countries; however, the countries that possess poor medical infrastructure lack awareness regarding the various types of Transthyretin Amyloidosis and its treatment. For instance, cardiac Amyloidosis was considered heart failure and was not given proper treatment for the longest period.

Minimal approved therapies to treat the condition are also considered as the major restraining factor for the growth of the Transthyretin Amyloidosis Market. The ATTR – PN is considered a difficult condition to recognize in the first place and then to manage. The rate of misdiagnosis is extremely common and if the diagnosis procedure is postponed, there is a higher risk of developing irreversible damage such as nerve cell damage, heart failure symptoms, constipation, and so on.

**Challenges:**

The awareness about the condition is considerably lower in several countries. This attribute has led to misleading medical advice and delay in proper medical assistance. Moreover, limitations in clinical trials and misleading knowledge about the condition are considered as the primary restraining factor for the growth of Transthyretin Amyloidosis. 

Poor medical infrastructure in several countries is considered as the major challenge in the growth of the Transthyretin Amyloidosis Market. Lack of knowledge about the condition and lack of advancements in the diagnostic procedures unlike other diagnostic procedures for the other health conditions is a primary challenge for the overall growth of the market. Since the condition cannot be cured completely, the inefficiency of the treatment is also considered as the major challenge for the overall growth of the Transthyretin Amyloidosis Market.

**Cumulative Growth Analysis:**

There are over 126 different genetic variations in Transthyretin Amyloidosis. Decades ago, there was minimal awareness among a wide range of populations regarding the condition, however, in recent times, the awareness about the condition is continuously increasing at a rapid pace. Initiatives by the government and non-governmental organizations have increased the overall growth of the Transthyretin Amyloidosis Market. 

A recent study shows that there were over 10,000 people per 100,000 people were living with the condition. The increasing mortality rate because of the condition has also augmented the steady growth of the Transthyretin Amyloidosis Market. The condition is most prevalent between 30 and 40 years of age, from then the condition is progressive. Bleeding under the skin, numbness in limbs, uncontrolled blood pressure, and fluctuations are some of the serious symptoms found in a patient that possesses the condition.

The advent of novel therapies including pipeline therapies and a combination of drugs and medications strategies are propelling the overall growth of the Transthyretin Amyloidosis Market. The market experts suggest that the market will witness steady growth if the combination strategies are further explored. On the other hand, drug developers are benefitting from increasing investments in [genetic testing](../../../reports/genetic-testing-market-2009) schemes. 

**Value Chain Analysis:**

The Familial amyloid polyneuropathy condition tends to grow into 100 different types of mutations which in turn lead to protein misfolding conditions. However, there is only a 50% chance for the child to acquire the condition if its parent or its closest relation has it. Transthyretin Amyloidosis was considered a rare condition that accounts for only 5% of the confirmed diagnosed rate in the earlier period. However, in recent years, the incidences are increasing, with the advancing diagnostic technologies. 

Moreover, there are over 4000 people presently living with the condition in the US. The increasing incidences are expected to present a lucrative opportunity for the overall growth of the Transthyretin Amyloidosis Market. Additionally, over 13% of heart failure in the region was assumed to be caused by Transthyretin Amyloidosis.

## **Transthyretin Amyloidosis (TTR) Market Segmentation**

### Based on Drug:

### Based on Indication**:**

### Based on distribution channel**:**

### Based on treatment:

**Regional analysis:**

North America and other parts of America are currently holding the highest market share in the Transthyretin Amyloidosis Market. The increasing prevalence of the condition and increasing geriatric population in the regions are the primary growth-stimulating attributes for the market. Every year there are over 5000 people are diagnosed with the condition in America. Moreover, the advancements in medical technology and the advent of new therapies in the market are augmenting the growth of the Transthyretin Amyloidosis Market. 

On the other hand, Europe is considered the second-largest Transthyretin Amyloidosis Market shareholder. A recent report shows that over 60 new cases are reported every year and over 12.9 million per year are diagnosed with the condition in the region. Such factors have propelled governmental organizations to boost up their investment in the market. The advancing medical infrastructure in the regions is also supporting the overall growth of the market.

**Competitive landscape:**

### Transthyretin Amyloidosis Market Industry Developments

- **Q4 2023: FDA approves WAINUA™ (eplontersen) for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults** Ionis Pharmaceuticals and AstraZeneca announced that the U.S. FDA approved WAINUA (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults, marking a significant regulatory milestone for the companies.[3]

**Report overview:**

**This report has covered:**

## Market Drivers

### Advancements in Therapeutic Options

Recent advancements in therapeutic options for transthyretin amyloidosis are poised to reshape the Global Transthyretin Amyloidosis Market Industry. Innovative treatments, including gene silencing therapies and monoclonal [antibodies](https://www.marketresearchfuture.com/reports/antibodies-market-20684), have shown promising results in clinical trials. These developments are expected to enhance patient outcomes and potentially reduce the burden of the disease. As new therapies gain regulatory approval, the market is likely to witness a shift towards more effective treatment modalities. This evolution in therapeutic landscape is anticipated to contribute to the market's growth, with projections indicating a market size of 13.1 USD Billion by 2035.

### Emerging Markets and Global Expansion

Emerging markets are playing a pivotal role in the expansion of the Global Transthyretin Amyloidosis Market Industry. As healthcare infrastructure improves in regions such as Asia-Pacific and Latin America, access to diagnostic and therapeutic options is increasing. This growth is further fueled by rising disposable incomes and a greater emphasis on healthcare spending. Pharmaceutical companies are strategically positioning themselves to tap into these markets, anticipating a surge in demand for transthyretin amyloidosis treatments. The global expansion of healthcare services is likely to create new opportunities for market players, contributing to the overall growth trajectory of the industry.

### Growing Awareness and Education Initiatives

The Global Transthyretin Amyloidosis Market Industry benefits significantly from growing awareness and education initiatives aimed at both healthcare professionals and the general public. Increased understanding of the disease's symptoms and progression is crucial for early diagnosis and intervention. Organizations and advocacy groups are actively promoting educational campaigns, which are likely to lead to a higher rate of diagnosis and treatment. As awareness continues to expand, the market is expected to see a corresponding increase in demand for therapeutic options. This trend underscores the importance of collaborative efforts in enhancing knowledge about transthyretin amyloidosis.

### Rising Investment in Research and Development

Investment in research and development within the Global Transthyretin Amyloidosis Market Industry is on the rise, driven by the urgent need for effective treatments. Pharmaceutical companies are increasingly allocating resources to explore novel therapeutic avenues, including small molecules and biologics. This commitment to innovation is crucial, as it not only addresses the unmet medical needs of patients but also fosters a competitive market environment. The anticipated compound annual growth rate of 7.63% from 2025 to 2035 reflects the industry's optimism regarding future breakthroughs. Enhanced funding for research initiatives is likely to accelerate the development of new therapies and improve patient care.

### Increasing Prevalence of Transthyretin Amyloidosis

The Global Transthyretin Amyloidosis Market Industry is experiencing a notable surge in prevalence, with an estimated 5.85 USD Billion market valuation in 2024. This increase is attributed to heightened awareness and improved diagnostic capabilities, leading to earlier identification of the disease. As healthcare professionals become more adept at recognizing symptoms, the number of diagnosed cases is expected to rise significantly. This trend not only underscores the importance of effective treatment options but also highlights the necessity for ongoing research and development in this field. The growing patient population is likely to drive demand for innovative therapies and management strategies.

## Future Outlook

The Transthyretin Amyloidosis Market is projected to grow at a 6.64% CAGR from 2025 to 2035, driven by advancements in therapies, increasing awareness, and improved diagnostic techniques.

**New opportunities:**

- Development of targeted gene therapies for hereditary forms
- Expansion of telehealth services for remote patient monitoring
- Partnerships with diagnostic companies for early detection solutions

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Cardiac Amyloidosis (Largest) vs. Polyneuropathy (Fastest-Growing)

In the Transthyretin Amyloidosis Market, the application segment is notably dominated by Cardiac Amyloidosis, which holds a significant market share due to its prevalence and serious health implications associated with the condition. Polyneuropathy, on the other hand, has emerged as a rapidly growing segment, leveraging advancements in treatment options and heightened awareness of the condition among healthcare providers and patients alike. Together, these segments reflect the nuanced landscape of the market, where differing patient needs and treatment possibilities drive varying levels of engagement and investment.

Cardiac Amyloidosis (Dominant) vs. Polyneuropathy (Emerging)

Cardiac Amyloidosis is recognized as the dominant application segment within the Transthyretin Amyloidosis Market, primarily due to its notable impact on patient morbidity and mortality rates. This condition often leads to severe cardiovascular complications, necessitating timely diagnosis and effective management strategies. In contrast, Polyneuropathy is positioned as an emerging segment, rapidly gaining traction as more patients are diagnosed with peripheral nerve involvement. Factors contributing to its growth include technological advancements in diagnostics and an increasing pipeline of therapies aimed at addressing neurological manifestations of amyloidosis. Both segments exhibit unique characteristics in terms of patient demographics and clinical management, shaping their respective trajectories in a competitive market.

### By Diagnosis Method: Biopsy (Largest) vs. Imaging Techniques (Fastest-Growing)

In the Transthyretin Amyloidosis Market, various diagnosis methods play a crucial role in identifying the disease. Currently, the biopsy stands out as the largest segment, with a significant share due to its reliability and accuracy in confirming transthyretin amyloidosis through histological analysis of tissues. Imaging techniques, on the other hand, are rapidly gaining traction, reflective of the increasing emphasis on non-invasive diagnostic approaches. This shift is driven by advancements in technology that enhance the sensitivity and specificity of imaging modalities, leading to improved patient outcomes.

Imaging Techniques (Dominant) vs. Blood Tests (Emerging)

Imaging techniques are becoming increasingly dominant in the diagnosis of transthyretin amyloidosis as they offer non-invasive methods to visualize amyloid deposits in various organs. These techniques, including MRI and ultrasound, are pivotal in assessing disease progression and organ involvement. Conversely, blood tests represent an emerging segment, providing insights into biomarker levels indicative of the disease. While blood tests are becoming more sophisticated with advances in genetic and metabolic profiling, they still lag behind imaging modalities in accuracy and comprehensive assessment, positioning them as a vital complementary tool rather than a standalone diagnostic solution.

### By Treatment Type: Pharmacological Therapy (Largest) vs. Gene Therapy (Fastest-Growing)

In the Transthyretin Amyloidosis Market, the treatment landscape is primarily dominated by Pharmacological Therapy, which holds the largest market share due to its established efficacy and widespread acceptance among healthcare professionals. Supportive Care also plays a crucial role, providing essential management of symptoms, but remains secondary in market share. [Gene Therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) and Stem Cell Transplantation represent emerging approaches, with Gene Therapy gaining traction as innovative solutions are developed that target the underlying causes of transthyretin amyloidosis directly.

Pharmacological Therapy (Dominant) vs. Gene Therapy (Emerging)

Pharmacological Therapy has long been the first line of treatment for transthyretin amyloidosis, offering a range of options, including tafamidis and diflunisal, which have proven effective in stabilizing the transthyretin protein. This segment is bolstered by ongoing clinical trials and enhancements in drug formulations. Conversely, Gene Therapy, while still in developmental stages, is seen as a groundbreaking advancement with the potential to cure the disease at the genetic level, showcasing significant promise due to technological advancements. Its ability to address root causes rather than just symptoms positions it as an exciting and rapidly evolving area in the treatment domain.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Transthyretin Amyloidosis Market, the patient demographics significantly influence therapeutic approaches and market dynamics. The Age Group segment represents the largest share, with older populations being more susceptible to this condition, consequently driving market demand towards age-appropriate treatment solutions. Gender, while traditionally less emphasized, is emerging as a crucial demographic factor, with a growing recognition of differences in disease manifestation and treatment responses between male and female patients.

Growth trends within the Patient Demographics segment are being driven by an aging population and increasing awareness of Transthyretin Amyloidosis among healthcare providers. As life expectancy rises, more patients are diagnosed, particularly in elderly cohorts. Additionally, targeted campaigns focusing on gender-specific symptoms are rapidly gaining traction, highlighting the importance of inclusive research and development methods to cater effectively to both male and female patients, thus fostering market growth.

Age Group: 65+ (Dominant) vs. 45-64 (Emerging)

The Age Group segment highlights the dominance of patients aged 65 and older, as they are more frequently diagnosed with Transthyretin Amyloidosis due to the degenerative nature of the disease, which tends to manifest later in life. This older demographic shows a significant need for specialized care and treatment options, which shapes the market landscape. In contrast, the 45-64 age group is emerging as an important segment due to increased awareness and improvements in early diagnosis, leading to a growing number of patients seeking treatment. This younger cohort is likely to drive future innovations in therapy as they advocate for better management strategies and awareness surrounding Transthyretin Amyloidosis.

### By Healthcare Setting: Hospitals (Largest) vs. Specialty Clinics (Fastest-Growing)

Within the Transthyretin Amyloidosis Market, hospitals represent the largest segment, capturing a significant share of the total market due to their comprehensive care capabilities and access to advanced treatment technologies. Specialty clinics, however, are emerging as the fastest-growing segment, benefiting from their focused expertise and targeted treatments that cater to the unique needs of patients suffering from transthyretin amyloidosis.

Healthcare Settings: Hospitals (Dominant) vs. Specialty Clinics (Emerging)

Hospitals remain the dominant force in the healthcare setting for transthyretin amyloidosis due to their extensive resources, including specialized medical personnel and treatment facilities. They provide broad-spectrum care from diagnosis to treatment and are equipped to handle complex cases. In contrast, specialty clinics are recognized as an emerging segment, offering personalized treatments and dedicated services tailored for transthyretin amyloidosis patients. Their specialized focus fosters innovation and attracts patients seeking targeted therapies, thus driving their rapid growth in the market.

## Regional Market Share Analysis

### North America : Leading Market Innovators

North America is poised to maintain its leadership in the Transthyretin Amyloidosis market, holding a significant market share of $3.0 billion in 2024. The region benefits from advanced healthcare infrastructure, increasing awareness of the disease, and a growing patient population. Regulatory support from agencies like the FDA has accelerated the approval of innovative therapies, driving demand for effective treatments.

The competitive landscape is robust, with key players such as Alnylam Pharmaceuticals, Pfizer, and Bristol-Myers Squibb leading the charge. These companies are heavily investing in research and development to enhance treatment options. The presence of established healthcare systems and a focus on patient-centric care further solidify North America's position as a market leader.

### Europe : Emerging Treatment Landscape

Europe is witnessing a burgeoning Transthyretin Amyloidosis market, projected to reach $1.8 billion by 2025. The region's growth is driven by increasing healthcare expenditure, heightened awareness of rare diseases, and supportive regulatory frameworks. Initiatives from the European Medicines Agency (EMA) are facilitating faster access to innovative therapies, thereby enhancing treatment availability for patients.

Leading countries such as Germany, France, and the UK are at the forefront of this market, with a strong presence of pharmaceutical giants like Pfizer and Bristol-Myers Squibb. The competitive landscape is characterized by strategic collaborations and partnerships aimed at advancing research. The focus on personalized medicine and patient access programs is expected to further propel market growth.

### Asia-Pacific : Emerging Market Potential

The Asia-Pacific region is emerging as a significant player in the Transthyretin Amyloidosis market, with a projected market size of $0.9 billion by 2025. Factors such as increasing healthcare investments, rising awareness of amyloidosis, and improving diagnostic capabilities are driving market growth. Regulatory bodies are also beginning to recognize the need for expedited approvals for rare disease treatments, which is expected to enhance market dynamics.

Countries like Japan and Australia are leading the charge, with key players such as Eisai Co., Ltd. and Amgen Inc. actively participating in the market. The competitive landscape is evolving, with a focus on local partnerships and collaborations to enhance treatment accessibility. As healthcare systems improve, the region is likely to see a surge in demand for effective therapies.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents an untapped market for Transthyretin Amyloidosis, with a market size of $0.28 billion projected by 2025. The growth is driven by increasing healthcare investments and a rising prevalence of rare diseases. However, challenges such as limited access to healthcare and regulatory hurdles remain. Governments are beginning to prioritize rare disease initiatives, which could catalyze market development.

Countries like South Africa and the UAE are showing potential, with a growing interest from pharmaceutical companies. The competitive landscape is still developing, with local and international players exploring opportunities. As awareness and healthcare infrastructure improve, the region is expected to gradually embrace innovative treatment options.

## Competitive Benchmarking

The Transthyretin Amyloidosis Market is characterized by a dynamic competitive landscape, driven by increasing awareness of the disease and advancements in therapeutic options. Key players such as Alnylam Pharmaceuticals (US), Pfizer (US), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Alnylam Pharmaceuticals (US) focuses on innovation through its RNA interference technology, which has shown promise in treating hereditary transthyretin amyloidosis. Meanwhile, Pfizer (US) emphasizes strategic partnerships to bolster its research capabilities and expand its product pipeline. Bristol-Myers Squibb (US) is leveraging its extensive experience in oncology to explore novel treatment avenues for transthyretin amyloidosis, indicating a trend towards cross-disciplinary approaches in drug development.The market structure appears moderately fragmented, with several players vying for dominance. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This trend is particularly evident as firms seek to mitigate risks associated with global supply chain disruptions. The collective influence of these key players shapes a competitive environment where innovation and operational efficiency are paramount.

In November  Alnylam Pharmaceuticals (US) announced a collaboration with a leading biotechnology firm to accelerate the development of its next-generation therapies for transthyretin amyloidosis. This strategic move is likely to enhance Alnylam's research capabilities and expedite the delivery of innovative treatments to patients, reinforcing its position as a leader in the market. The collaboration underscores the importance of partnerships in driving innovation and addressing unmet medical needs.

In October  Pfizer (US) launched a new initiative aimed at increasing patient access to its transthyretin amyloidosis therapies in emerging markets. This initiative includes educational programs for healthcare professionals and patients, which may significantly enhance treatment uptake. By focusing on access and education, Pfizer is not only expanding its market reach but also contributing to improved patient outcomes, which is increasingly recognized as a critical factor in the pharmaceutical industry.

In September  Bristol-Myers Squibb (US) completed the acquisition of a small biotech firm specializing in amyloidosis research. This acquisition is expected to bolster Bristol-Myers Squibb's pipeline and enhance its capabilities in developing targeted therapies. The strategic importance of this move lies in the potential to integrate innovative research into its existing portfolio, thereby accelerating the development of new treatment options for patients suffering from transthyretin amyloidosis.

As of December  current competitive trends in the Transthyretin Amyloidosis Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to deliver cutting-edge therapies and ensure patient access, thereby fostering a more sustainable and patient-centric market environment.

## Recent News & Developments

Pfizer has received FDA approval for Vyndaqel (tafamidis) as a treatment for wild-type ATTR amyloidosis, based on clinical data showing significant benefits in reducing cardiac complications.

**July 2024**

Ionis has introduced IONIS-TTR-LRx, a new antisense oligonucleotide drug, with promising clinical trials indicating stronger efficacy and improved safety compared to existing therapies.

Transthyretin Amyloidosis Market is a progressive disease that includes an abnormal buildup of abnormal proteins under the skin or in organs like kidneys, heart, eyes, brain, or tissues. The diseases have implications for organs and the peripheral nervous system. There are two presentations of the condition which are Transthyretin amyloid polyneuropathy and Transthyretin amyloid cardiomyopathy. 

In Transthyretin amyloid polyneuropathy, the amyloid fibrils are deposited in the peripheral nervous system and Transthyretin Amyloid cardiomyopathy, the deposits are made on the heart which could lead to heart failure. The type of the condition is majorly dependent on the type of protein that is deposited in the organs. 

The symptoms could get worse over time and varies according to the protein deposits. Amyloid buildup in the nerves can permanently affect the nervous system and eventually loss of sensation in limbs, hands, and feet. Although they primarily affect the voluntary functions of the patients, they tend to affect the involuntary body functions such as blood pressure, heart rate, digestion, and so on. The survival chances are only 7 years from the disease onset. These factors are primarily responsible for the overall growth of the Transthyretin Amyloidosis Market.

**COVID 19 Analysis:**

The pandemic has significantly affected major health concerns and various other health sectors. The physicians have tries different methods in assisting patients to offer a potential treatment. Especially physicians have found it very challenging in handling COVID-infected ATTR patients. Since Transthyretin Amyloidosis Market is a progressive disease, they tend to develop multi-organ complications due to COVID infection.

The delays in the diagnosis and interrupted treatment due to movement restrictions across several countries have inflicted significant risks for the patients with Transthyretin Amyloidosis Market. Additionally, patients and doctors found the changing trend of the treatment procedure, while ensuring to reduce the interruptions in treatments.

## Report Scope

| MARKET SIZE 2024 | 5.98(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.45(USD Billion) |
| MARKET SIZE 2035 | 12.18(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.64% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Prothena Corporation (US), Akcea Therapeutics (US) |
| Segments Covered | Application, Diagnosis Method, Treatment Type, Patient Demographics, Healthcare Setting |
| Key Market Opportunities | Advancements in gene therapies and novel therapeutics enhance treatment options in the Transthyretin Amyloidosis Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the Transthyretin Amyloidosis market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Transthyretin Amyloidosis Market?**
A: As of 2024, the Transthyretin Amyloidosis Market was valued at 5.98 USD Billion.

**Q: What is the projected market size for the Transthyretin Amyloidosis Market by 2035?**
A: The market is projected to reach 12.18 USD Billion by 2035.

**Q: What is the expected CAGR for the Transthyretin Amyloidosis Market during the forecast period?**
A: The expected CAGR for the Transthyretin Amyloidosis Market from 2025 to 2035 is 6.64%.

**Q: Which companies are the key players in the Transthyretin Amyloidosis Market?**
A: Key players include Alnylam Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Ionis Pharmaceuticals, Eisai Co., Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Horizon Therapeutics.

**Q: What are the main applications of treatments in the Transthyretin Amyloidosis Market?**
A: The main applications include Cardiac Amyloidosis, Polyneuropathy, Cerebral Amyloidosis, and Ocular Amyloidosis, with valuations ranging from 1.07 to 4.25 USD Billion.

**Q: How is the Transthyretin Amyloidosis Market segmented by diagnosis method?**
A: The market is segmented into Biopsy, Imaging Techniques, Blood Tests, and Genetic Testing, with values from 1.0 to 3.66 USD Billion.

**Q: What treatment types are included in the Transthyretin Amyloidosis Market?**
A: Treatment types include Pharmacological Therapy, Supportive Care, Gene Therapy, and Stem Cell Transplantation, with valuations between 1.19 and 4.88 USD Billion.

**Q: How does patient demographics affect the Transthyretin Amyloidosis Market?**
A: The market considers factors like Age Group, Gender, Genetic Predisposition, and Comorbid Conditions, with valuations from 1.19 to 3.65 USD Billion.

**Q: What healthcare settings are involved in the Transthyretin Amyloidosis Market?**
A: Healthcare settings include Hospitals, Specialty Clinics, Home Healthcare, and Research Institutions, with values ranging from 0.9 to 4.85 USD Billion.

**Q: What trends are anticipated in the Transthyretin Amyloidosis Market by 2035?**
A: By 2035, the market is likely to experience growth driven by advancements in treatment options and increased awareness of the disease.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155*